Knowledge hub

The evolution of pulmonary & nasal drug delivery

Physicians have treated illness with inhaled remedies for thousands of years. The pressurized metered-dose inhalers (pMDIs) used today differ dramatically from the pipes, reeds, and pots used centuries ago, but the benefits of inhalation devices have stood the test of time. As the inventors of the original pMDI, Kindeva draws on this legacy to develop […]

What happens when large-scale manufacturing meets full-service CDMO capabilities?

In the ever-evolving pharmaceutical and biotechnology industries, the demand for seamless integration between large-scale manufacturing and full-service CDMO capabilities has never been more critical. In this article by Chad Hafer, discover how access to the process, range of services, and capacity is crucial to minimize risk, lower costs, and streamline timelines through every stage of […]

What’s next for CDMO supply chains?

How CDMOs Can Develop a More Seamless Supply Chain Recent pharmaceutical industry market dynamics have tested the resolve of contract development and manufacturing organizations (CDMOs) of all sizes. To maintain business vitality, several CDMOs have been forced to consider the difficult decision to stop manufacturing products that are too complex or too expensive to make […]

Missed ss at DDL? Unlock pulmonary & nasal insights with our presentations 

Kindeva Drug Delivery presented cutting-edge advancements in pulmonary & nasal development and manufacturing at the Drug Delivery to the Lungs (DDL) conference on December 6-8, 2023. Across eight posters and podium presentations, we highlighted strategies for switching to green propellant formulations while preserving product performance, among a variety of other topics. If you missed any […]

Manufacturing microneedle products presentation

Access Now

The pMDI dilemma: managing patient needs, human health, and the planet

The pMDI dilemma: managing patient needs, human health, and the planet

While long a topic of discussion, an even brighter spotlight has illuminated the subject of more environmentally friendly inhalers of late, thanks in part to the proposed phasedown on per- and polyfluoroalkyl substances (PFAS). PFAS substances as a class are comprised of thousands of synthetic chemicals that resist degradation because of their exceptionally strong chemical […]

Promising early results for new high-performance DPI

The αeolus, developed in a collaboration between Kindeva Drug Delivery and Cambridge Healthcare Innovations, is a passive, high-performance, high-consistency dry powder inhaler (DPI) platform concept. This technology has produced promising preliminary results, addressing common concerns with passive DPIs through innovative engineering and novel technologies. Download this article to delve into the performance of the αeolus […]

Understanding the in-vitro/in-vivo relationship (IVIVR): inhaled medicinal products

In-vitro/in-vivo relationship (IVIVR) modeling leverages in-vitro testing knowledge in order to predict in-vivo results. This can often reduce long-term development costs and facilitate more informed decision making. Download this article to uncover how IVIVR works in practice and how Kindeva has demonstrated expertise in this area.